Trps1 targets Ccnd1 to regulate mouse Leydig cell proliferation

The role and mechanism of quercetin in improving late-onset hypogonadism through network analysis and experimental validation

The rising incidence of late-onset hypogonadism (LOH) profoundly diminishes the quality of life in men due to declining testosterone levels. Quercetin is an important active metabolite in various traditional botanical drugs that enhance male fertility, yet its mechanisms of action remain unclear. This study delves into the therapeutic potential and underlying mechanisms of quercetin in LOH management, proposing novel treatment strategies. An aging murine model was created and treated with quercetin starting at 12 weeks of age. Sperm parameters were evaluated, and serum and testicular testosterone and inflammatory cytokines were quantified via ELISA. Histological analyses of testicular tissue were performed. Network analysis and molecular docking studies predicted quercetin's therapeutic pathways in LOH. Key proteins involved in testosterone synthesis and testicular aging were verified using western blotting and immunofluorescence. Aged TM3 cells were treated with quercetin to corroborate the effects on testicular Leydig cells. In the murine model, the quercetin treatment group showed an increase in sperm average path velocity (VAP) by 1.21 ± 0.087-fold (p < 0.01), an increase in straight-line velocity (VCL) by 1.12 ± 0.18-fold (p < 0.01), a rise in serum testosterone levels by 0.27 ± 0.48-fold (p < 0.05), and an increase in testosterone levels in testicular tissue by 0.30 ± 0.20-fold (p < 0.05), while IL-1β levels decreased to 0.61 ± 0.13-fold (p < 0.01) compared to the aging group. Network analysis suggested quercetin's efficacy in LOH may be mediated through the AR and PI3K/AKT pathways. In quercetin-treated aged mice, a reduction in γH2AX and an increase in Ki67 expression were observed in testicular tissue, alongside upregulated expression of key testosterone synthesis proteins-steroidogenic acute regulatory (STAR) and scavenger receptor class B type 1 (SRB1), accompanied with enhanced AR expression and AKT1 phosphorylation. Similar results were confirmed in testicular Leydig cells. Compared to the group treated with bleomycin alone, the bleomycin plus quercetin treatment group showed a reduced positive area in β-gal staining, downregulation of the senescence-associated marker γH2AX, increased expression of the key testosterone synthesis protein SRB1, and elevated levels of expression of quercetin's potential target AR as well as phosphorylation of AKT1. Quercetin ameliorates the aging of testicular Leydig cells and promotes testosterone synthesis through modulation of the AR/PI3K/AKT signaling pathway, presenting a promising therapeutic approach for LOH.

Trps1 regulates mouse zygotic genome activation and preimplantation embryo development via the PDE4D/AKT/CREB signaling pathway

Despite zygotic genome activation (ZGA) is crucial for early embryonic development, its regulatory mechanism is still unclear in mammals. In the present study, we demonstrate that TRPS1, a maternal factor, plays an essential role in mouse early embryogenesis by regulating the transition from 2-cell to 4-cell embryos during preimplantation development. The absence of Trps1 could leads to impaired ZGA through AKT/CREB signaling pathway. Furthermore, our findings suggest that TRPS1 may modulate the transcription of Pde4d to influence AKT and CREB phosphorylation. Interestingly, compared to Trps1 knockdown alone, co-injection of Trps1 siRNA and Pde4d mRNA significantly enhances the development rate of 4-cell embryos. Collectively, these results indicate a negative involvement of Trps1 in mouse preimplantation embryo development by targeting the PDE4D/AKT/CREB pathway to regulate ZGA.

Analysis of the function, mechanism and clinical application prospect of TRPS1, a new marker for breast cancer

It has been discovered that Trichorhinophalangeal Syndrome-1 (TRPS1), a novel member of the GATA transcription factor family, participates in both normal physiological processes and the development of numerous diseases. Recently, TRPS1 has been identified as a new biomarker to aid in cancer diagnosis and is very common in breast cancer (BC), especially in triple-negative breast cancer (TNBC). In this review, we discussed the structure and function of TRPS1 in various normal cells, focused on its role in tumorigenesis and tumor development, and summarize the research status of TRPS1 in the occurrence and development of BC. We also analyzed the potential use of TRPS1 in guiding clinically personalized precision treatment and the development of targeted drugs.

Down-regulation of miR-138-5p in PP2A KO mice promoted apoptosis of spermatocytes

BACKGROUND

Protein phosphatase 2 A (PP2A) is known to have a pivotal and diverse functions in various physiological processes. In the previous study, we utilized the cre-loxp system to generate germ cell-specific knockout mice for the PP2A catalytic subunit alpha subunit (Ppp2cacKO).

METHODS AND RESULTS

Using high-throughput miRNA sequencing of testis tissues and real‑time PCR, we have identified a notable decrease in the expression of miR-138-5p in the testes of Ppp2cacKO mice. Our findings indicate that miR-138-5p plays a role in the regulation of apoptosis and proliferation of GC2 cells. Furthermore, bioinformatics analyses suggested that miR-138- 5p may target the transcriptional repressor Trps1. Consistent with these predictions, we observed a significant upregulation of Trps1 in the testes of Ppp2cacKO mice. Through transfection experiments, we have validated the negative regulation of Trps1 expression by miR-138-5p in GC2 cells.

CONCLUSION

Our study indicates that the down-regulation of miR-138-5p in PP2A KO mice, which targets Trps1 to promote spermatocyte apoptosis.

Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma

TRPS1 is aberrantly expressed in a variety of tumors, including breast, prostate, and gastric cancers, and is strongly associated with tumorigenesis or prognosis. However, the role of TRPS1 in high grade serous ovarian carcinoma (HGSC) is unknown. We investigated the relationship between TRPS1 expression and clinicopathology in HGSC patients. The tumor-related regulatory mechanisms of TRPS1 was explored through in vivo and vitro experiments. The results showed that TRPS1 was highly expressed in HGSC compared to normal tissues. It was also linked to the cell proliferation index Ki67 and poor prognosis. In vivo experiments showed that knockdown of TRPS1 could inhibit tumor growth. In vitro experiments, knockdown of TRPS1 inhibited the proliferation of ovarian cancer cells. TRPS1 exerted its regulatory role as a transcription factor, binding to the PSAT1 promoter and promoting the expression of PSAT1 gene. Meanwhile, PSAT1 was positively correlated with CCND1 expression. These results suggest that TRPS1 affects HGSC proliferation and cell cycle by regulating PSAT1 and thus CCND1 expression.

Trps1 acts as a regulator of Sf-1 transcription and testosterone synthesis in mouse Leydig cells

Infertility has attracted global concern, and disruption of testosterone is a common cause of male infertility. Exploring the critical factors in testosterone biosynthesis may provide new insights for disease research and clinical therapy. Research on trichorhinophalangeal syndrome-1 (Trps1) gene has recently been focus on cancers; it is yet unknown whether Trps1 produces a marked effect in the male reproductive system. In the current study, single-cell RNA sequencing analysis of trichorhinophalangeal syndrome-1 gene (Trps1) expression in mouse testes and cleavage under targets and tagmentation and RNA sequencing were utilized to investigate the functionality of Trps1 in mouse Leydig cells. Knockdown of Trps1 increased testosterone synthesis in vitro and vivo using adeno-associated viral delivery and conditional knockout models. The results showed that Trps1 was abundantly expressed in Leydig cells. The expression levels of both steroidogenic factor-1 (Sf-1) and steroidogenic enzymes (Cyp11a1, Hsd3b, Cyp17a1, and Hsd17b3) as well as testosterone secretion were increased after Trps1 deficiency in vivo and vitro. Furthermore, disruption of Trps1 reduced histone deacetylase 1/2 activity and increased histone H3 acetylation in the Sf-1 promoter, thereby promoting testosterone secretion. Interestingly, Sf-1 also regulated the transcription of Trps1 through activating transcription factor 2. These results indicate that Trps1 targets Sf-1 to affect steroidogenesis through histone acetylation and shed light on the critical role of Trps1 functioning in the mouse Leydig cells.

Integrated analysis of microRNA expression profiles and function network in mice testes after low dose lead exposure from early puberty

There is evidence suggesting the participation of non-coding RNAs in male reproductive dysfunction induced by lead, and the significance of microRNAs has been highlighted recently because of their essential roles in gene regulatory networks. To comprehensively understand the functions of miRNA and the regulatory networks, RNA sequencing was carried out to obtain miRNA expression profiles in mice testes exposed to low dose Pb for 90 days at the onset of puberty. In total, 44 differentially expressed miRNAs with 26 up-regulated and 18 down-regulated were identified between 200 mg/L Pb group and control group (p < 0.05). Enrichment analysis confirmed that the target genes of DE miRNAs might participate in the metabolism of testicular cells. Furthermore, a miRNA-mRNA co-expression network consisting of 19 miRNAs and 106 mRNAs and a competing endogenous RNA network of lncRNA-miRNA-mRNA including 179 genes were established. Finally, the expressions of 4 miRNAs (mmu-miR-451a, mmu-miR-133a-3p, mmu-miR-1a-3p and mmu-miR-486a-3p) and 4 mRNAs (Gramd1b, Tcf7l2, Mov10 and Srcin1) involved in regulatory networks were verified by RT-qPCR. In conclusion, our research might provide targets for the mechanism studies of miRNAs in reproductive toxicity of Pb.

Functional mechanisms of TRPS1 in disease progression and its potential role in personalized medicine

The gene of transcriptional repressor GATA binding 1 (TRPS1), as an atypical GATA transcription factor, has received considerable attention in a plethora of physiological and pathological processes, and may become a promising biomarker for targeted therapies in diseases and tumors. However, there still lacks a comprehensive exploration of its functions and promising clinical applications. Herein, relevant researches published in English from 2000 to 2022 were retrieved from PubMed, Google Scholar and MEDLINE, concerning the roles of TRPS1 in organ differentiation and tumorigenesis. This systematic review predominantly focused on summarizing the structural characteristics and biological mechanisms of TRPS1, its involvement in tricho-rhino-phalangeal syndrome (TRPS), its participation in the development of multiple tissues, the recent advances of its vital features in metabolic disorders as well as malignant tumors, in order to prospect its potential applications in disease detection and cancer targeted therapy. From the clinical perspective, the deeply and thoroughly understanding of the complicated context-dependent and cell-lineage-specific mechanisms of TRPS1 would not only gain novel insights into the complex etiology of diseases, but also provide the fundamental basis for the development of therapeutic drugs targeting both TRPS1 and its critical cofactors, which would facilitate individualized treatment.